In vitro evaluation of novel compounds against selected resistant Pseudomonas aeruginosa isolates.
We describe the activities of RX-P763, RX-P766, RX-P770, RX-P792, RX-P793, and RX-P808 against strains of resistant Pseudomonas aeruginosa. These compounds target the large subunit of the bacterial ribosome and have broad-spectrum activities against multidrug-resistant pathogens. All compounds demonstrated in vitro activity against P. aeruginosa, with MIC(90) values of 4 to 8 μg/ml (range, 0.5 to 64). These novel compounds had narrow MIC distributions and maintained activity despite resistance phenotypes to other commonly utilized agents.
Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
Seth T
ST
Housman
Christina
C
Sutherland
David P
DP
Nicolau
D000900:Anti-Bacterial Agents / Q000138:chemical synthesis / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000494:pharmacology; D003596:Cytosine / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology*; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D011758:Pyrroles / Q000138:chemical synthesis / Q000494:pharmacology*; D054681:Ribosome Subunits, Large, Bacterial; D014031:Tobramycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D011758:Pyrroles; D002939:Ciprofloxacin; D003596:Cytosine; D014031:Tobramycin